Clinical Trial News and Research

RSS

Intensive early treatment slows down progression of type 2 diabetes

Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

28 Jun 2012

BPI clinical study to evaluate computerized, brain-plasticity-based program for schizophrenia

Researchers at San Francisco-based Brain Plasticity, Inc. (BPI) have begun a multi-center study to evaluate the effects of a computerized, brain-plasticity-based program designed to address the cognitive issues associated with schizophrenia.

28 Jun 2012

CHLA pediatric oncologist receives Hyundai Hope on Wheels grant

Weili Sun, MD, PhD, a pediatric oncologist at Children's Hospital Los Angeles, was awarded $75,000 by the Hyundai Hope on Wheels program. She will use this money to further her research into the role of epigenetics in cancer.

28 Jun 2012

Full results from Derma Sciences’ DSC127 Phase 2 trial on diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that full results from its successful Phase 2 clinical trial with the investigational drug DSC127 in patients with diabetic foot ulcers will be published on July 5th in the July 2012 issue of Wound Repair and Regeneration.

28 Jun 2012

Combination of radiation therapies effectively treat prostate cancer, lower chances of recurrence

A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.

27 Jun 2012

MAARA invests £340,000 into vital asthma and allergy research

A charity operating Britain's longest-running pollen database is investing over £340,000 into vital asthma and allergy research at the University of Leicester.

27 Jun 2012

SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

27 Jun 2012

Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

27 Jun 2012

First clinical trial to test cardiac drug regimen for DMD

The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

$Postoperative hemoglobin predicts hospital stay after hip fracture surgery$

Postoperative hemoglobin predicts hospital stay after hip fracture surgery

Postoperative anemia is associated with longer hospital stays following surgery for hip fracture, Dutch researchers report.

26 Jun 2012

Toothpaste is enough for baby’s teeth

Using chlorhexidine gel on infants’ teeth achieves no more than using fluoride toothpaste alone to prevent early childhood caries, show the results of a randomized, controlled clinical trial.

26 Jun 2012

LOGIC-Insulin software more effectively controls blood-sugar levels among critically ill patients

A computer-software program more effectively controlled blood-sugar levels among critically ill patients than nurse-directed care did, according to the first large clinical trial of its kind. The results will be presented at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Clinical trial to examine functional benefits of combined therapy against stroke

Researchers at Vanderbilt University Medical Center are leading an international clinical trial to examine the functional benefits of a combined therapy to treat acute ischemic stroke, a type of stroke where a blood clot becomes lodged in an artery within the brain, reducing blood flow and depriving brain cells of oxygen. Eighty-seven percent of strokes are ischemic.

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Sinovac provides update on EV71 vaccine Phase III trial on HFMD

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).

26 Jun 2012

Exercise and diet together reduce chances of developing metabolic syndrome in obese older adults

Obese older adults can reduce their chance of developing the metabolic syndrome by losing weight through dieting alone, but adding exercise to a weight loss program has even more benefit, a new study finds. The results, to be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston, show that a combination of diet-induced weight loss and frequent exercise almost doubled the improvement in insulin sensitivity compared with dieting alone.

25 Jun 2012

FDA approves Daiichi Sankyo's US-based Bethlehem packaging facility

Today, Daiichi Sankyo, Inc. received U.S. Food and Drug Administration (FDA) approval to package product at its first United States-based packaging facility located in Bethlehem, PA. With this approval, the Company expands its global supply chain capability, helping to ensure the supply of medicine to U.S. physicians and their patients.

25 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

BV treatment: full enrolment for phase 2 and first phase 3 trial

Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) is pleased to report that recruitment is now 100% complete for its Phase 2 clinical trial to investigate the ability of VivaGel® to prevent the recurrence of BV, and also for the first of two pivotal Phase 3 studies of VivaGel® for the treatment of BV.

25 Jun 2012